Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.

ABSTRACT:

Purpose

Conivaptan is an intravenous dual V_1A/V₂ vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients with mild hepatic impairment needed no dose adjustment. The objective of this Phase 1, open-label study was to assess the pharmacokinetics, protein binding, and safety of 48 h of conivaptan infusion in individuals with severe hepatic impairment.

Patients and methods

Eight subjects with severe hepatic impairment (Child-Pugh score 10-15) and nine subjects with normal liver function were enrolled. Intravenous conivaptan (20 mg) was given as a 30 min loading dose on Da

SUBMITTER: Marbury T 

PROVIDER: S-EPMC5315214 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature